Millipore Sigma Vibrant Logo

480415 NF023 - Calbiochem

A suramin analog that acts as a selective and direct G-protein antagonist for α-subunits of the Go/Gi group (EC₅₀ ~ 300 nM).

NF023 - Calbiochem: MSDS (material safety data sheet) o SDS, certificato d’analisi (CoA) e certificato di qualità (CoQ), dossier, brochure e altri documenti disponibili.

Sinonimi: 8,8ʹ-[Carbonylbis(imino-3,1-phenylene)]bis-(1,3,5-naphthalenetrisulfonic Acid), 6Na, P2X Antagonist I, Purinergic Receptor P2X Antagonist I

Primary Target: α-subunits of the Go/Gi group of G-protein
View Products on Sigmaaldrich.com
480415
Visualizza prezzi e disponibilità

Panoramica

Replacement Information

Tabella delle specifiche principali

Empirical Formula
C₃₅H₂₀N₄O₂₁S₆ · 6Na

Prezzi e disponibilità

Numero di catalogo DisponibilitàConfezionamento Qtà/conf Prezzo Quantità
480415-10MG
Verifica della disponibilità in corso...
—
Disponibilità limitata Disponibilità limitata
A magazzino 
Fuori produzione
Disponibili quantità limitate
La disponibilità deve essere confermata
    Prodotti rimanenti: riceverà un nostro avviso
      Prodotti rimanenti: riceverà un nostro avviso
      Will advise
      Contatti il Servizio Clienti
      Contact Customer Service

      		 Fiala di plastica 10 mg
      Ricerca del prezzo in corso...
      Non è stato possibile trovare il prezzo
      La quantità minima deve essere un multiplo di
      Maximum Quantity is
      Al termine dell'ordine Maggiori informazioni
      Lei ha salvato ()
       
      —
      Richiedi il prezzo
      		 —
      Description
      OverviewA suramin analog that acts as a selective and direct G-protein antagonist for α-subunits of the Go/Gi group (EC50 ~ 300 nM). Suppresses GTPγS binding to recombinant G-protein α-subunits. Acts by inhibiting the formation of the agonist-specific ternary complex (agonist/receptor/G-protein). NF023 does not interfere with the interaction between α-subunits and βγ-dimer but competes with the effector binding site. Also a P2X receptor antagonist (IC50 = 240 nM for P2X1; 8.5 µM for P2X3 receptor in rat muscle). Causes a concentration dependent inhibition of excitatory junction potentials (IC50 = 4.8 pM).
      Catalogue Number480415
      Brand Family Calbiochem®
      Synonyms8,8ʹ-[Carbonylbis(imino-3,1-phenylene)]bis-(1,3,5-naphthalenetrisulfonic Acid), 6Na, P2X Antagonist I, Purinergic Receptor P2X Antagonist I
      References
      ReferencesSnedden, P., et al. 2000. Br. J. Pharmacol. 129, 1089.
      Soto, F., et al. 1999. Neuropharmacology 38, 141.
      Beindle, W., et al. 1996. Mol. Pharmacol. 50, 415.
      Freissmuth, M., et al. 1996. Mol. Pharmacol. 49, 602.
      Product Information
      ATP CompetitiveN
      FormWhite to off-white solid
      Hill FormulaC₃₅H₂₀N₄O₂₁S₆ · 6Na
      Chemical formulaC₃₅H₂₀N₄O₂₁S₆ · 6Na
      Hygroscopic Hygroscopic
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Targetα-subunits of the Go/Gi group of G-protein
      Primary Target IC<sub>50</sub>240 nM for P2X1; 8.5 µM for P2X3 receptor in rat muscle; 4.8 pM in the inhibition of excitatory junction potentials; EC50 ~ 300 nM as G-protein antagonist for α-subunits of the Go/Gi group
      Purity≥95% by HPLC
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Avoid freeze/thaw cycles of solutions.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Numero di catalogo GTIN
      480415-10MG 04055977201345

      Documentation

      NF023 - Calbiochem MSDS

      Titolo

      Scheda di sicurezza (MSDS) 

      NF023 - Calbiochem Certificati d'Analisi

      TitoloNumero di lotto
      480415

      Riferimenti bibliografici

      Panoramica delle referenze
      Snedden, P., et al. 2000. Br. J. Pharmacol. 129, 1089.
      Soto, F., et al. 1999. Neuropharmacology 38, 141.
      Beindle, W., et al. 1996. Mol. Pharmacol. 50, 415.
      Freissmuth, M., et al. 1996. Mol. Pharmacol. 49, 602.
      Scheda tecnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision19-June-2018 JSW
      Synonyms8,8ʹ-[Carbonylbis(imino-3,1-phenylene)]bis-(1,3,5-naphthalenetrisulfonic Acid), 6Na, P2X Antagonist I, Purinergic Receptor P2X Antagonist I
      DescriptionA suramin analog that acts as a selective G-protein antagonist for α-subunits of the Go/Gi group (EC50 ~300 nM). Suppresses GTPγS binding to recombinant G-protein α-subunits. Acts by inhibiting the formation of the agonist-specific ternary complex (agonist/receptor/G-protein). NF023 does not interfere with the interaction between α-subunits βγ-dimer but competes with the effector binding site. Also a P2X receptor antagonist (IC50=0.24 µM for P2X1; 8.5 µM for P2X3 receptor in rat muscle).
      FormWhite to off-white solid
      Intert gas (Yes/No) Packaged under inert gas
      Chemical formulaC₃₅H₂₀N₄O₂₁S₆ · 6Na
      Structure formulaStructure formula
      Purity≥95% by HPLC
      SolubilityH₂O
      Storage +2°C to +8°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Avoid freeze/thaw cycles of solutions.
      Toxicity Standard Handling
      ReferencesSnedden, P., et al. 2000. Br. J. Pharmacol. 129, 1089.
      Soto, F., et al. 1999. Neuropharmacology 38, 141.
      Beindle, W., et al. 1996. Mol. Pharmacol. 50, 415.
      Freissmuth, M., et al. 1996. Mol. Pharmacol. 49, 602.